Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care. Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest from Eliza Slawther
England’s health technology assessment institute, NICE, must ensure that there is clarity for manufacturers on how its methods and processes might change following testing in its sandbox environment, the Association of the British Pharmaceutical Industry said.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
The European Health Data Space Regulation is deliberately “vague” when it comes to defining trade secrets because the EU wants the pharma industry to make recommendations on safeguarding intellectual property, a policy officer for the European Commission says.
England’s health technology assessment institute explains how its sandbox environment is helping to test new evaluation methods for drugs or indications with which it does not have experience, such as metabolic dysfunction-associated steatohepatitis.
European pharma trade associations EFPIA and EUCOPE outline their respective views on how the EU’s pharma legislation overhaul should tackle antimicrobial resistance, and why transferable exclusivity vouchers alone will not suffice as incentives.
Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.